Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
23 results
  • Colorectal Cancer, Lung Cancer

20-177          Phase I

A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors

  • Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Melanoma

21-184          Phase I

A Phase 1, First-in-Human Study of DCC-3116 as a Single Agent and in Combination with Trametinib in Patients with Advanced or Metastatic Solid Tumors with RAS or RAF Mutations

  • Bladder Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer

23-452          Phase I

A Phase 1, First-in-Human, Dose Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

  • Pancreatic Cancer, Colorectal Cancer, Lung Cancer

23-123          Phase II

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients with Advanced Solid Tumors Harboring a KRAS G12D Mutation

  • Lung Cancer, Gastric (Stomach) Cancer, Colorectal Cancer

23-340          Phase II

A Phase 1/2 Study of FOG-001 in Participants with Locally Advanced or Metastatic Solid Tumors

  • Colorectal Cancer

22-334          Phase II

A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNDX-5613 in Patients with Colorectal Cancer

  • Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Breast Cancer, Lung Cancer

22-577          Phase II

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)

  • Melanoma, Lung Cancer, Colorectal Cancer, Pancreatic Cancer

22-595          Phase II

A Phase 1/2A Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination with BGB-3245 in Patients with Advanced Solid Tumors

  • Colorectal Cancer, Lung Cancer

21-398          Phase I

A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors

  • Cervical Cancer, Breast Cancer, Bladder Cancer, Colorectal Cancer, Endometrial Cancer, Gastric (Stomach) Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma

23-392          Phase I

A Phase 1a/1b, Dose-Escalation/Dose-Expansion study of NPX267 in Subjects with Solid Tumors Known to Express HHLA-2

Showing 1 - 10 of 23 results